Kodai Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Kodai Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$3.52M	Buy	+468,799	New	+$3.78M	0.14%	114

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kodai Capital Management's BCRX Position: Q1 2025 in Review

Kodai Capital Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2025: 468,799 shares worth $3.52M. The stake represents 0.14% of the portfolio and ranks #114 among its holdings.

274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.

Kodai Capital Management held 468,799 shares of BioCryst Pharmaceuticals worth $3.52M as of Q1 2025.
BioCryst Pharmaceuticals was a new Kodai Capital Management position in Q1 2025.
BioCryst Pharmaceuticals made up 0.14% of Kodai Capital Management's portfolio in Q1 2025, its #114 holding.
274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.

Based on Kodai Capital Management's 13F filing for Q1 2025, filed 15 May 2025.